Monte Rosa Therapeutics/$GLUE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Ticker

$GLUE
Primary listing

Industry

Biotechnology

Employees

142

ISIN

US61225M1027

GLUE Metrics

BasicAdvanced
$363M
76.14
$0.08
1.41
-

What the Analysts think about GLUE

Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.

Bulls say / Bears say

Monte Rosa Therapeutics secured a global licensing agreement with Novartis, including a $150 million upfront payment and potential milestones up to $2.1 billion, significantly enhancing its financial position and validating its molecular glue degrader technology. (stocktwits.com)
The company's MRT-6160, targeting VAV1 for immune-mediated conditions, demonstrated promising preclinical results, leading to a strategic partnership with Novartis to advance its development. (benzinga.com)
Monte Rosa's collaboration with Roche to develop molecular glue degraders for cancer and neurological diseases, with an upfront payment of $50 million and potential milestones exceeding $2 billion, underscores strong industry confidence in its platform. (benzinga.com)
Despite significant partnerships, Monte Rosa reported a net loss of $72.7 million for the year ended December 31, 2024, indicating ongoing financial challenges. (monterosatx.com)
The company's cash position decreased from $377 million at the end of 2024 to $331 million by March 31, 2025, reflecting substantial cash burn and operational expenses. (stocktitan.net)
Monte Rosa's reliance on milestone payments from partnerships introduces revenue uncertainty, as these payments are contingent upon successful development and regulatory approvals. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 14 Jul 2025.

GLUE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GLUE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GLUE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs